Analysis of GP73 in patients with HCC as a function of anti-cancer treatment

Hie-Won Hann; Mengjun Wang; Julie Hafner; Ronald E Long; Su Hee Kim; Meejin Ahn; Susan Park; Mary Ann Comunale; Timothy M Block; Anand Mehta

doi:10.3233/cbm-2010-0190

Analysis of GP73 in patients with HCC as a function of anti-cancer treatment

Hie-Won Hann, Mengjun Wang, Julie Hafner, Ronald E Long, Su Hee Kim, Meejin Ahn, Susan Park, Mary Ann Comunale, Timothy M Block, Anand Mehta

Department of Bio-Medical Sciences (PCOM)

Research output: Contribution to journal › Article › peer-review

Abstract

In this study, we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-treatment) showed reductions in GP73 at the first time point available post-treatment. In contrast, patients who had high levels GP73 post treatment all had re-occurrence within a 5 year period. These data are preliminary but dramatically imply that this marker may have value in the monitoring of HCC patients and may be elevated even when small, undetectable tumors are present.

Original language	American English
Journal	Cancer Biomarkers
Volume	7
DOIs	https://doi.org/10.3233/cbm-2010-0190
State	Published - Jun 2011

Disciplines

Cancer Biology

Access to Document

10.3233/cbm-2010-0190License: Unspecified

Cite this

@article{213f96390de642a2a3528082db939a50,

title = "Analysis of GP73 in patients with HCC as a function of anti-cancer treatment",

abstract = " In this study, we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-treatment) showed reductions in GP73 at the first time point available post-treatment. In contrast, patients who had high levels GP73 post treatment all had re-occurrence within a 5 year period. These data are preliminary but dramatically imply that this marker may have value in the monitoring of HCC patients and may be elevated even when small, undetectable tumors are present. ",

author = "Hie-Won Hann and Mengjun Wang and Julie Hafner and Long, {Ronald E} and Kim, {Su Hee} and Meejin Ahn and Susan Park and Comunale, {Mary Ann} and Block, {Timothy M} and Anand Mehta",

note = "In this study, we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-",

year = "2011",

month = jun,

doi = "10.3233/cbm-2010-0190",

language = "American English",

volume = "7",

journal = "Cancer Biomarkers",

}

TY - JOUR

T1 - Analysis of GP73 in patients with HCC as a function of anti-cancer treatment

AU - Hann, Hie-Won

AU - Wang, Mengjun

AU - Hafner, Julie

AU - Long, Ronald E

AU - Kim, Su Hee

AU - Ahn, Meejin

AU - Park, Susan

AU - Comunale, Mary Ann

AU - Block, Timothy M

AU - Mehta, Anand

N1 - In this study, we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-

PY - 2011/6

Y1 - 2011/6

N2 - In this study, we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-treatment) showed reductions in GP73 at the first time point available post-treatment. In contrast, patients who had high levels GP73 post treatment all had re-occurrence within a 5 year period. These data are preliminary but dramatically imply that this marker may have value in the monitoring of HCC patients and may be elevated even when small, undetectable tumors are present.

AB - In this study, we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-treatment) showed reductions in GP73 at the first time point available post-treatment. In contrast, patients who had high levels GP73 post treatment all had re-occurrence within a 5 year period. These data are preliminary but dramatically imply that this marker may have value in the monitoring of HCC patients and may be elevated even when small, undetectable tumors are present.

UR - https://doi.org/10.3233/cbm-2010-0190

U2 - 10.3233/cbm-2010-0190

DO - 10.3233/cbm-2010-0190

M3 - Article

VL - 7

JO - Cancer Biomarkers

JF - Cancer Biomarkers

ER -

Analysis of GP73 in patients with HCC as a function of anti-cancer treatment

Abstract

Disciplines

Access to Document

Other files and links

Cite this